Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAIR
NL-OMON50519Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabotegravir, rilpivirine, abacavir, dolutegravir and lamivudine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Started Jan 2017; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirineabacavirdolutegravirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON50519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50519.